Skip to main content
Top
Published in: Pituitary 2/2024

25-01-2024 | Hypophysitis

Successful treatment of medically and surgically refractory lymphocytic hypophysitis with fractionated stereotactic radiotherapy: a single-center experience and systematic literature review

Authors: Mehdi Khaleghi, Guilherme Finger, Kyle C. Wu, Vikas Munjal, Luma Ghalib, Peter Kobalka, Dukagjin Blakaj, Khaled Dibs, Ricardo Carrau, Daniel Prevedello

Published in: Pituitary | Issue 2/2024

Login to get access

Abstract

Purpose

To explore the potential role of focused radiotherapy in managing the lymphocytic hypophysitis (LH) refractory to medical therapy and surgery.

Method

A systematic literature review was conducted following PRISMA guidelines to identify the studies on radiation treatment for hypophysitis, along with the experience in our institution.

Results

The study included eight patients, three from our institution and five from existing literature. The age at presentation ranged from 37 to 75 years old, with a median age of 58. The presenting symptoms involved headache in seven patients and diplopia in two patients. Pre-radiation visual field defects were noticed in four patients. All patients exhibited variable degrees of hypopituitarism before radiation, with oral corticosteroids being the initial medical treatment. Immunosuppressive therapy was attempted in two patients prior to radiation. Seven patients had a history of transsphenoidal surgery with a histologically confirmed LH. Three patients underwent stereotactic radiosurgery (SRS), while the remaining received FSRT, with a mean irradiation volume of 2.2 cm3. A single-session total dose of 12 -15 Gy was administered in the SRS group. In the FSRT group, doses ranged from 24 to 30 Gy with a median dose of 25 Gy, delivered in 2 Gy fractions. Four patients achieved a resolution of visual field defects, while another two patients demonstrated improvement in their associated focal neurologic deficits. No change in pre-existing endocrine status was shown after radiation, except in one patient. Clinical response was achieved in seven patients after a single course of radiation, while one patient required the second course. Six patients remained stable on low-dose glucocorticoid during at least a 12-month follow-up period, and one discontinued it entirely without experiencing relapse. Three patients demonstrated a complete radiologic response, while the remaining showed a partial radiologic response.

Conclusions

Focused radiation, including FSRT, can play a role in symptomatic relief, effective mass shrinkage, and minimizing radiation exposure to critical surrounding structures in patients with refractory LH. However, further research efforts are necessary to better clarify its effects and optimal dose planning.
Literature
1.
2.
go back to reference Leung GK et al (2004) Primary hypophysitis: a single-center experience in 16 cases. J Neurosurg 101(2):262–271CrossRefPubMed Leung GK et al (2004) Primary hypophysitis: a single-center experience in 16 cases. J Neurosurg 101(2):262–271CrossRefPubMed
3.
go back to reference Minakshi B, Alok S, Hillol KP (2005) Lymphocytic hypophysitis presenting as pituitary apoplexy in a male. Neurol India 53(3):363–364CrossRefPubMed Minakshi B, Alok S, Hillol KP (2005) Lymphocytic hypophysitis presenting as pituitary apoplexy in a male. Neurol India 53(3):363–364CrossRefPubMed
4.
go back to reference Bensing S et al (2007) Lymphocytic hypophysitis: report of two biopsy-proven cases and one suspected case with pituitary autoantibodies. J Endocrinol Invest 30(2):153–162CrossRefPubMed Bensing S et al (2007) Lymphocytic hypophysitis: report of two biopsy-proven cases and one suspected case with pituitary autoantibodies. J Endocrinol Invest 30(2):153–162CrossRefPubMed
5.
go back to reference Yamagami K et al (2003) Treatment of lymphocytic hypophysitis by high-dose methylprednisolone pulse therapy. Intern Med 42(2):168–173CrossRefPubMed Yamagami K et al (2003) Treatment of lymphocytic hypophysitis by high-dose methylprednisolone pulse therapy. Intern Med 42(2):168–173CrossRefPubMed
6.
go back to reference Selch MT et al (2003) Stereotactic radiotherapy for the treatment of lymphocytic hypophysitis. Rep Two Cases J Neurosurg 99(3):591–596 Selch MT et al (2003) Stereotactic radiotherapy for the treatment of lymphocytic hypophysitis. Rep Two Cases J Neurosurg 99(3):591–596
7.
go back to reference Donaldson SS et al (1980) Treatment of orbital pseudotumor (idiopathic orbital inflammation) by radiation therapy. Int J Radiat Oncol Biol Phys 6(1):79–86CrossRefPubMed Donaldson SS et al (1980) Treatment of orbital pseudotumor (idiopathic orbital inflammation) by radiation therapy. Int J Radiat Oncol Biol Phys 6(1):79–86CrossRefPubMed
8.
go back to reference Keleti D et al (1992) Radiotherapy of lymphoproliferative diseases of the orbit. Surveillance of 65 cases. Am J Clin Oncol 15(5):422–427PubMed Keleti D et al (1992) Radiotherapy of lymphoproliferative diseases of the orbit. Surveillance of 65 cases. Am J Clin Oncol 15(5):422–427PubMed
9.
go back to reference Conn DL (2001) Resolved: Low-dose prednisone is indicated as a standard treatment in patients with rheumatoid arthritis. Arthritis Rheum 45(5):462–467CrossRefPubMed Conn DL (2001) Resolved: Low-dose prednisone is indicated as a standard treatment in patients with rheumatoid arthritis. Arthritis Rheum 45(5):462–467CrossRefPubMed
10.
go back to reference Gubbi S et al (2019) Hypophysitis: an update on the novel forms, diagnosis and management of disorders of pituitary inflammation. Best Pract Res Clin Endocrinol Metab 33(6):101371CrossRefPubMedPubMedCentral Gubbi S et al (2019) Hypophysitis: an update on the novel forms, diagnosis and management of disorders of pituitary inflammation. Best Pract Res Clin Endocrinol Metab 33(6):101371CrossRefPubMedPubMedCentral
11.
go back to reference Angelousi A et al (2018) Clinical, endocrine and imaging characteristics of patients with primary hypophysitis. Horm Metab Res 50(4):296–302CrossRefPubMed Angelousi A et al (2018) Clinical, endocrine and imaging characteristics of patients with primary hypophysitis. Horm Metab Res 50(4):296–302CrossRefPubMed
12.
go back to reference Chalan P, Thomas N, Caturegli P (2021) Th17 cells contribute to the pathology of autoimmune hypophysitis. J Immunol 206(11):2536–2543CrossRefPubMed Chalan P, Thomas N, Caturegli P (2021) Th17 cells contribute to the pathology of autoimmune hypophysitis. J Immunol 206(11):2536–2543CrossRefPubMed
13.
go back to reference Langlois F, Varlamov EV, Fleseriu M (2021) Hypophysitis, the growing spectrum of a rare pituitary disease. J Clin Endocrinol Metab 107(1):10–28CrossRefPubMedCentral Langlois F, Varlamov EV, Fleseriu M (2021) Hypophysitis, the growing spectrum of a rare pituitary disease. J Clin Endocrinol Metab 107(1):10–28CrossRefPubMedCentral
14.
15.
go back to reference Pekic S et al (2018) Lymphocytic hypophysitis successfully treated with stereotactic radiosurgery: case report and review of the literature. J Neurol Surg A Cent Eur Neurosurg 79(1):77–85CrossRefPubMed Pekic S et al (2018) Lymphocytic hypophysitis successfully treated with stereotactic radiosurgery: case report and review of the literature. J Neurol Surg A Cent Eur Neurosurg 79(1):77–85CrossRefPubMed
16.
go back to reference Hendrickx A, Bossuyt X (2001) Quantification of the leukocyte common antigen (CD45) in mature B-cell malignancies. Cytometry 46(6):336–339CrossRefPubMed Hendrickx A, Bossuyt X (2001) Quantification of the leukocyte common antigen (CD45) in mature B-cell malignancies. Cytometry 46(6):336–339CrossRefPubMed
17.
go back to reference Lee EJ et al (2017) CD3 and CD20 immunohistochemical staining patterns of bone marrow-infiltrating malignant lymphoma cells. Ann Clin Lab Sci 47(2):136–143PubMed Lee EJ et al (2017) CD3 and CD20 immunohistochemical staining patterns of bone marrow-infiltrating malignant lymphoma cells. Ann Clin Lab Sci 47(2):136–143PubMed
18.
go back to reference O’Connell FP, Pinkus JL, Pinkus GS (2004) CD138 (syndecan-1), a plasma cell marker immunohistochemical profile in hematopoietic and nonhematopoietic neoplasms. Am J Clin Pathol 121(2):254–263CrossRefPubMed O’Connell FP, Pinkus JL, Pinkus GS (2004) CD138 (syndecan-1), a plasma cell marker immunohistochemical profile in hematopoietic and nonhematopoietic neoplasms. Am J Clin Pathol 121(2):254–263CrossRefPubMed
19.
go back to reference Lecube A et al (2003) Lymphocytic hypophysitis successfully treated with azathioprine: first case report. J Neurol Neurosurg Psychiatry 74(11):1581–1583CrossRefPubMedPubMedCentral Lecube A et al (2003) Lymphocytic hypophysitis successfully treated with azathioprine: first case report. J Neurol Neurosurg Psychiatry 74(11):1581–1583CrossRefPubMedPubMedCentral
20.
go back to reference Schreckinger M et al (2012) Novel strategy to treat a case of recurrent lymphocytic hypophysitis using rituximab. J Neurosurg 116(6):1318–1323CrossRefPubMed Schreckinger M et al (2012) Novel strategy to treat a case of recurrent lymphocytic hypophysitis using rituximab. J Neurosurg 116(6):1318–1323CrossRefPubMed
21.
go back to reference Gubbi S et al (2018) Primary hypophysitis and other autoimmune disorders of the sellar and suprasellar regions. Rev Endocr Metab Disord 19(4):335–347CrossRefPubMed Gubbi S et al (2018) Primary hypophysitis and other autoimmune disorders of the sellar and suprasellar regions. Rev Endocr Metab Disord 19(4):335–347CrossRefPubMed
22.
go back to reference Honegger J et al (2015) Treatment of primary hypophysitis in Germany. J Clin Endocrinol Metab 100(9):3460–3469CrossRefPubMed Honegger J et al (2015) Treatment of primary hypophysitis in Germany. J Clin Endocrinol Metab 100(9):3460–3469CrossRefPubMed
23.
go back to reference Fitzpatrick PJ, Macko S (1984) Lymphoreticular tumors of the orbit. Int J Radiat Oncol Biol Phys 10(3):333–340CrossRefPubMed Fitzpatrick PJ, Macko S (1984) Lymphoreticular tumors of the orbit. Int J Radiat Oncol Biol Phys 10(3):333–340CrossRefPubMed
24.
go back to reference Biswas R et al (2020) Inflammatory myofibroblastic tumor of maxillary sinus successfully treated with radiotherapy and corticosteroid: report of a rare case. J Egypt Natl Canc Inst 32(1):26CrossRefPubMed Biswas R et al (2020) Inflammatory myofibroblastic tumor of maxillary sinus successfully treated with radiotherapy and corticosteroid: report of a rare case. J Egypt Natl Canc Inst 32(1):26CrossRefPubMed
25.
go back to reference Najjar N et al (2022) Very low-dose radiation therapy for management of inflammatory myofibroblastic tumor of the lung. Rare Tumors 14:20363613221106270CrossRefPubMedPubMedCentral Najjar N et al (2022) Very low-dose radiation therapy for management of inflammatory myofibroblastic tumor of the lung. Rare Tumors 14:20363613221106270CrossRefPubMedPubMedCentral
26.
go back to reference Minniti G et al (2014) Fractionated stereotactic radiosurgery for patients with brain metastases. J Neurooncol 117(2):295–301CrossRefPubMed Minniti G et al (2014) Fractionated stereotactic radiosurgery for patients with brain metastases. J Neurooncol 117(2):295–301CrossRefPubMed
27.
go back to reference Sallabanda K et al (2011) Stereotactic radiosurgery in pituitary adenomas: long-term single institution experience and role of the hypothalamic-pituitary axis. J Radiosurg SBRT 1(3):213–220PubMedPubMedCentral Sallabanda K et al (2011) Stereotactic radiosurgery in pituitary adenomas: long-term single institution experience and role of the hypothalamic-pituitary axis. J Radiosurg SBRT 1(3):213–220PubMedPubMedCentral
28.
go back to reference Minniti G et al (2016) Stereotactic radiotherapy and radiosurgery for non-functioning and secreting pituitary adenomas. Rep Pract Oncol Radiother 21(4):370–378CrossRefPubMed Minniti G et al (2016) Stereotactic radiotherapy and radiosurgery for non-functioning and secreting pituitary adenomas. Rep Pract Oncol Radiother 21(4):370–378CrossRefPubMed
29.
go back to reference Carvalho HA, Villar RC (2018) Radiotherapy and immune response: the systemic effects of a local treatment. Clinics (Sao Paulo) 73(suppl 1):e557sCrossRefPubMed Carvalho HA, Villar RC (2018) Radiotherapy and immune response: the systemic effects of a local treatment. Clinics (Sao Paulo) 73(suppl 1):e557sCrossRefPubMed
30.
go back to reference Tripathi M et al (2021) Role of stereotactic radiosurgery in intracranial histiocytosis: a systematic review of literature of an emerging modality for localized disease. World Neurosurg 150:64–70CrossRefPubMed Tripathi M et al (2021) Role of stereotactic radiosurgery in intracranial histiocytosis: a systematic review of literature of an emerging modality for localized disease. World Neurosurg 150:64–70CrossRefPubMed
31.
go back to reference Kuntz L et al (2022) Radionecrosis after repeated courses of radiotherapy under stereotactic conditions for brain metastases: analysis of clinical and dosimetric data from a retrospective cohort of 184 patients. Cancer Radiother 26(5):692–702CrossRefPubMed Kuntz L et al (2022) Radionecrosis after repeated courses of radiotherapy under stereotactic conditions for brain metastases: analysis of clinical and dosimetric data from a retrospective cohort of 184 patients. Cancer Radiother 26(5):692–702CrossRefPubMed
32.
33.
go back to reference Sheehan JP et al (2005) Stereotactic radiosurgery for pituitary adenomas: an intermediate review of its safety, efficacy, and role in the neurosurgical treatment armamentarium. J Neurosurg 102(4):678–691CrossRefPubMed Sheehan JP et al (2005) Stereotactic radiosurgery for pituitary adenomas: an intermediate review of its safety, efficacy, and role in the neurosurgical treatment armamentarium. J Neurosurg 102(4):678–691CrossRefPubMed
Metadata
Title
Successful treatment of medically and surgically refractory lymphocytic hypophysitis with fractionated stereotactic radiotherapy: a single-center experience and systematic literature review
Authors
Mehdi Khaleghi
Guilherme Finger
Kyle C. Wu
Vikas Munjal
Luma Ghalib
Peter Kobalka
Dukagjin Blakaj
Khaled Dibs
Ricardo Carrau
Daniel Prevedello
Publication date
25-01-2024
Publisher
Springer US
Published in
Pituitary / Issue 2/2024
Print ISSN: 1386-341X
Electronic ISSN: 1573-7403
DOI
https://doi.org/10.1007/s11102-023-01367-8

Other articles of this Issue 2/2024

Pituitary 2/2024 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.